LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

Search

CareDx Inc

Abierto

SectorSanidad

19.55 -1.41

Resumen

Variación precio

24h

Actual

Mínimo

19.33

Máximo

19.96

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.336

110.024

Margen de beneficios

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-9.68% downside

Dividendos

By Dow Jones

Próximas Ganancias

24 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

259M

1B

Apertura anterior

20.96

Cierre anterior

19.55

Noticias sobre sentimiento de mercado

By Acuity

16%

84%

27 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 feb 2026, 22:31 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Ganancias

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Ganancias

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Ganancias

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Charlas de Mercado

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Charlas de Mercado
Ganancias

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Charlas de Mercado

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Charlas de Mercado

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Ganancias

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Charlas de Mercado

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Ganancias

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Ganancias

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Ganancias

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Charlas de Mercado

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Ganancias

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Ganancias

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Ganancias

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

-9.68% descenso

Estimación a 12 Meses

Media 18 USD  -9.68%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

0

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

27 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat